Clinical Trial: Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Brief Summary: The purpose of this study is to test the safety and effectiveness of durvalumab with tremelimumab in patients with relapsed or refractory germ cell tumors.

Detailed Summary:
Sponsor: Memorial Sloan Kettering Cancer Center

Current Primary Outcome: Best confirmed overall response [ Time Frame: 1 year ]

Response will be evaluated according to RECIST v1.1, with a modification to account for the role of tumor marker evaluation in Germ Cell Tumor response assessment.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Memorial Sloan Kettering Cancer Center

Dates:
Date Received: May 16, 2017
Date Started: May 15, 2017
Date Completion: November 2019
Last Updated: May 16, 2017
Last Verified: May 2017